Christopher J. Senner - 11 Jun 2026 Form 4 Insider Report for Quince Therapeutics, Inc. (QNCX)

Reporting relationship: Director
Issuer ticker: QNCX
Reported as of: 11 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 15 Jun 2026, 17:51:59 UTC
Prior SEC filing: 19 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Brendan Hannah as attorney-in-fact for Christopher J. Senner

Key filing fact

Christopher J. Senner filed Form 4 for Quince Therapeutics, Inc. (QNCX) on 15 Jun 2026.

Key facts

This page summarizes Christopher J. Senner's Form 4 filing for Quince Therapeutics, Inc. (QNCX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 15 Jun 2026, 17:51.

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

CIK 0001648367 Primary reporting owner

Relationship: Director
Address: C/O QUINCE THERAPEUTICS, INC., 611 GATEWAY BLVD., SUITE 273, SOUTH SAN FRANCISCO
Signature: /s/ Brendan Hannah as attorney-in-fact for Christopher J. Senner
Signature date: 15 Jun 2026

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

QNCX transaction Derivative

Award

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Explanation of responses 1 footnote

Footnote F1

100% of the shares subject to this stock option will vest on the one-year anniversary of the grant date.